Molecular Formula | C21H19Cl2N5O2 |
Molar Mass | 444.31 |
Density | 1.44 |
Boling Point | 672.6±55.0 °C(Predicted) |
Solubility | DMSO |
pKa | 12.93±0.40(Predicted) |
Storage Condition | -20℃ |
In vitro study | LY2874455 inhibited FGF/FGFR-mediated signaling activity in RT-112 cells, HUVECs,KATO-III cells, and SNU-16 cells. LY2874455 showed FGFR-dependent anti-proliferative effects in KMS-11,OPM-2,SNU-16 and KATO-III cells. LY2874455 inhibits FGF/FGFR-mediated signaling activity in RT-112 cells, HUVECs,KATO-III cells, and SNU-16 cells. LY2874455 showed FGFR-dependent anti-proliferative effects in KMS-11,OPM-2,SNU-16 and KATO-III cells. |
In vivo study | In mouse heart tissue, LY2874455 exhibited potent inhibition of FGF-induced Erk phosphorylation with TED50 and TED90 values of 1.3 and 3.2 mg/kg, respectively. LY2874455 (3 mg/kg p.o.) dose-dependently inhibited tumor growth in mice bearing RT-112,OPM-2 (DSMZ),SNU-16, or NCI-H460 xenografts. in mouse heart tissue, LY2874455 exhibited potent inhibition of FGF-induced Erk phosphorylation with TED50 and TED90 values of 1.3 and 3.2 mg/kg, respectively. LY2874455 (3 mg/kg p.o.) dose-dependently inhibited tumor growth in mice bearing RT-112,OPM-2 (DSMZ),SNU-16, or NCI-H460 xenografts. |